Bio-Rad Laboratories Class BBIO.B
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 8,030
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
14% more funds holding
Funds holding: 7 [Q1] → 8 (+1) [Q2]
0.02% less ownership
Funds ownership: 0.09% [Q1] → 0.07% (-0.02%) [Q2]
38% less capital invested
Capital invested by funds: $1.5M [Q1] → $935K (-$563K) [Q2]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for BIO.B.